Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adjuvant chemotherapy in colon carcinoma stages II and III

Adjuvant chemotherapy in colon carcinoma stages II and III Adjuvant chemotherapy significantly improves disease-free survival and overall survival in colon cancer. Ongoing clinical trials are evaluating the addition of targeted therapies to standard regimen and the influence of gene expression signature as prognostic and predictive markers for the use of adjuvant chemotherapy. This review will summarize adjuvant therapeutic approaches in stages III and II colon cancer as well as therapeutic options in elderly patients and future developments in the adjuvant setting of colon cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Adjuvant chemotherapy in colon carcinoma stages II and III

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/adjuvant-chemotherapy-in-colon-carcinoma-stages-ii-and-iii-MsH0Ho9J56
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0253-8
Publisher site
See Article on Publisher Site

Abstract

Adjuvant chemotherapy significantly improves disease-free survival and overall survival in colon cancer. Ongoing clinical trials are evaluating the addition of targeted therapies to standard regimen and the influence of gene expression signature as prognostic and predictive markers for the use of adjuvant chemotherapy. This review will summarize adjuvant therapeutic approaches in stages III and II colon cancer as well as therapeutic options in elderly patients and future developments in the adjuvant setting of colon cancer.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 30, 2011

References

  • Levamisol and fluorouracil for adjuvant therapy of resected colon carcinoma
    Moertel, CG; Fleming, TR; Macdonald, JS
  • Intergroup study of flurouracil plus levamisole as adjuvant therapy for stage II/Dukes'B2 colon cancer
    Moertel, CG; Fleming, TR; Macdonald, JS
  • Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01
    Porschen, R; Bermann, A; Löffler, T
  • Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04
    Wolmark, N; Rockette, H; Mamounas, E
  • Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
    O'Connell, MJ; Laurie, JA; Kahn, M
  • Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancers: Five-year final report of INT-0089
    Haller, D; Catalano, P; Macdonald, J
  • Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluoruracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
    Köhne, CH; Wils, J; Lorenz, M
  • Capecitabine as adjuvant treatment for stage III colon cancer
    Twelves, C; Wong, A; Nowacki, MP
  • Oral uracil and Tegafur plus leucovorin compared with intravenous flourouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    Lembersky, BC; Wieand, HS; Petrelli, NJ
  • Ralitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in adjuvant Colon Cancer 01 (PETACC-1)
    Popov, I; Carrato, A; Sobrero, A
  • Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the adjuvant treatment of colon cancer (MOSAIC)
    André, T; Boni, C; Mounedji-Boudiaf, L
  • Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
    Kuebler, JP; Wieand, HS; O'Connell, MJ
  • First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin versus bolus 5-FU/LV for stage III colon cancer
    Haller, DG; Tabernero, J; Maroun, J
  • Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)
    Saltz, LB; Niedzwiecki, D; Hollis, D
  • Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
    Van Cutsem, E; Labianca, R; Bodoky, G
  • A phase III randomised trial of LV5FU2 + Irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
    Ychou, M; Raoul, JL; Douillard, JY
  • Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much?
    Gill, S; Loprinzi, CL; Sargent, DJ
  • Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
    Gray, R; Barnwell, J; McConkey, C
  • End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group
    Sargent, DJ; Patiyil, S; Yothers, G
  • American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Benson, AB; Schrag, D; Somerfiled, MR
  • A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients
    Sargent, DJ; Goldberg, RM; Jacobson, SD
  • Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/III colon cancer: findings from the ACCENT Database
    McCleary, J; Meyerhardt, J; Green, E
  • Phase II randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV in patients with metastatic colorectal cancer
    Kabbinavar, F; Hurwitz, H; Fehrenbacher, L
  • Bevacizumab plus irinotecan, flurouracil and leucovorin for metastatic colorectal cancer
    Hurwitz, H; Fehrenbacher, L; Novotny, W
  • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Saltz, L; Diaz-Rubio, E; Scheithauer, W
  • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Van Cutsem, E; Köhne, CH; Hitre, E
  • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
    Douillard, JY
  • Randozmized phase III study of Panitumumab with fluorouracil, leucovorin and irinotectan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    Peeters, M
  • Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08
    Allegra, CJ; Yothers, G; O'Connell, MJ
  • Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG intergroup phase III trial N0147
    Alberts, SR; Sargent, DJ; Smyrk, TC
  • Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
    Sargent, DJ; Marsoni, S; Monges, G
  • Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy
    Kim, ST; Lee, J; Park, SH
  • Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803
    Bertagnolli, MM; Niedzwiecki, D; Compton, CC
  • Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
    Salazar, R; Roepman, P; Capella, G
  • Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
    Roth, AD; Tejpar, S; Delorenzi, M
  • Physical activity and survival after colorectal cancer diagnosis
    Meyerhardt, JA; Giovannucci, EL; Holmes, MD
  • Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
    Meyerhardt, JA; Heseltine, D; Niedwiecki, D